JP4723899B2 - 皮膚外用組成物 - Google Patents
皮膚外用組成物 Download PDFInfo
- Publication number
- JP4723899B2 JP4723899B2 JP2005128631A JP2005128631A JP4723899B2 JP 4723899 B2 JP4723899 B2 JP 4723899B2 JP 2005128631 A JP2005128631 A JP 2005128631A JP 2005128631 A JP2005128631 A JP 2005128631A JP 4723899 B2 JP4723899 B2 JP 4723899B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- component
- external composition
- tranexamic acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 48
- -1 tranexamic acid ester Chemical class 0.000 claims description 27
- 229960000401 tranexamic acid Drugs 0.000 claims description 24
- 229920002545 silicone oil Polymers 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- FNNJSYRQSGKSAY-UHFFFAOYSA-N hexadecyl 4-(aminomethyl)cyclohexane-1-carboxylate Chemical group CCCCCCCCCCCCCCCCOC(=O)C1CCC(CN)CC1 FNNJSYRQSGKSAY-UHFFFAOYSA-N 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 83
- 238000005259 measurement Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 17
- 230000037303 wrinkles Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 102400000686 Endothelin-1 Human genes 0.000 description 9
- 101800004490 Endothelin-1 Proteins 0.000 description 9
- 239000006071 cream Substances 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 5
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000005068 transpiration Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- ADEORFBTPGKHRP-UHFFFAOYSA-N 1-[7-(dimethylamino)-4-methyl-2-oxochromen-3-yl]pyrrole-2,5-dione Chemical compound O=C1OC2=CC(N(C)C)=CC=C2C(C)=C1N1C(=O)C=CC1=O ADEORFBTPGKHRP-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003501 anti-edematous effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940112419 brilliant green / gentian violet Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/445—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Description
A成分は、トラネキサム酸エステル及び/又はその塩であり、特に制限されるものではないが、下記式(1)で表される化合物又はその誘導体が好適である。
B成分であるシリコーン油としては、通常化粧料や外用剤に使用されているものを用いることができ、例えば、ジメチルポリシロキサン、ジメチルシクロポリシロキサン、メチルフェニルポリシロキサン、ポリエーテル変性ポリシロキサン、アミノ変性ポリシロキサン、アルコール変性ポリシロキサン、アクリル変性ポリシロキサン、架橋型ジメチルポリシロキサン、架橋型メチルフェニルポリシロキサン等が挙げられる。これらは単独で用いてもよく、2種類以上を組み合わせて用いてもよい。これらのかなでも、例えばジメチルポリシロキサン、ジメチルシクロポリシロキサン、メチルフェニルポリシロキサンを用いると、粘着性が抑えられ、皮膚の‘べたつき’感や油性感(油っぽさ)を軽減することができる。なお、これらのシリコーン油は、1種又は2種以上を選択して使用することができる。
皮膚外用組成物として、下記表2に示す組成(処方)のクリームを定法にて調製した。
実施例1及び比較例1〜5のクリーム(皮膚外用組成物)について、肌状態の改善作用、シワ改善作用等の皮膚に与える作用効果を、以下に示す試験によって測定評価した。
被験者
目尻に肉眼で認識できるシワを持つ男性(年齢:35歳から40歳) 10名を1群とし、表1記載の各クリームを塗布した6つの皮膚外用組成物適用群と、クリームを塗布しない1つの無塗布群(以下、「ブランク」という)の合計7群を形成した。
各群の被験者の顔面に被験試料を1日2回、朝夜に適量を塗布した。
連続して8週間行い、皮膚状態 として以下の項目を試験開始直前、4週間後及び8週間後に測定した。
(1)皮膚表面水分量
(2)経表皮水分蒸散量(TEWL)
(3)皮膚色
(4)皮膚粘弾性
(5)剥離角層診断
(6)シワ深さの計測
被験者を恒温恒湿室(22℃、相対湿度45%)に入れ、15分間安静にして環境に順化させた後、以下の(1)〜(5)に示す手順にて測定を行った。なお、下記(1)〜(6)のいずれにおいても、各測定値についてStudent t検定又はWilcoxson検定による有意差検定を行い、ブランクとしての無塗布群と皮膚外用組成物適用群との差異を評価した。
皮膚表面水分量測定装置SKICON200(I.B.S. Co., Ltd.製)を用いて単位面積当たりの電気伝導度(mS/cm2)を測定した。測定は5回実施し、そのうち安定した3回の測定値の平均値をその部位の皮膚表面水分量とした。なお、皮膚表面水分量の増加は肌状態の改善を表す指標の一つである。測定結果を図1に示す。同図中、ブランク、及び実施例1の測定データを、黒塗り四角印、及び黒塗り丸印で示す。また、各比較例の測定データを白抜き丸印で示す。さらに、図中の実線及び破線は、プロットした各データをブランク、実施例及び比較例毎に結ぶ目安線である。また、実線B、実線E1、及び破線C1〜C5は、それぞれブランク、実施例1、比較例1〜5であることを示す(以下、図2〜9において同様とする。)。
経表皮水分蒸散量(TEWL)は、2チャンネル水分蒸散モニターAS−TW2(ASAHI BIOMED社製)を用いて測定した。測定は3回実施し、その平均値をTEWL(g/cm2/h)とした。なお、TEWL値の減少は肌状態の改善を表す指標の一つである。測定結果を図2に示す。
皮膚色は接触型測色計CM−2022(ミノルタ社製)を用いてL*a*b*表色系を用いて測定した。L*値の測定は3回行い、その平均値をもってL*値とした。L*値の上昇は皮膚色の白色化を表す指標の一つである。測定結果を図3に示す。
皮膚粘弾性はキュートメーターSEM575CK(electronic Gmb.)社製を用いて測定した。皮膚のハリの指標としてR2値(R2=Ua/Uf、Ua:吸引開放時の皮膚の戻り、Uf:吸引時の皮膚の伸び)を用いて評価した。なお、R2値の上昇は皮膚粘弾性の改善を表す指標の一つである。測定結果を図4に示す。
皮膚を消毒用エタノールにて清拭後、市販のセロハンテープ(30×24 mm)を用いて角層細胞を剥離した。剥離された角層細胞をスライドグラスに移しとったものを、ブリリアントグリーン・ゲンチアナバイオレット(BG)染色およびN-(7-Dimethylamino-4-methyl-3-coumarinyl) maleimide(DACM)染色用の試料とした。診断パラメーターとしては、角層細胞面積、角層細胞剥離パターン(多重剥離度)、有核細胞率、及び遊離のSH基に起因するSH染色度を用いた。なお、角層細胞面積の減少は表皮ターンオーバー速度の促進を表す指標の一つである。また、角層細胞剥離パターンの減少、有核細胞率の減少、及びSH染色度の減少はいずれも正常な角化を表す指標の一つである。各々の測定結果を図5〜図8に示す。
まず、レプリカ剤を用いて目尻に存在するシワの鋳型(レプリカ)を採取した。次いで、その鋳型に対し、シワの主たる走行方向に直交する方向から且つ斜め30゜の上方より光をあててシワの影を生じせしめた。さらに、その画像解析を行い、生じたシワの影の深さを計測した。なお、レプリカ剤としては、微細な形態の転写が可能で、レプリカ採取としての実績報告が数多くあるSILFLO(Flexico.England社製)を用いた。結果を図9に示す。
図1〜9より、上記すべての測定項目において、実施例1のクリームは、比較例1〜5のクリームよりも高い改善効果を示すことが判明した。このことから、本発明の皮膚外用組成物が、シワ及び肌状態を有意に改善し且つ皮膚の白色化を十分に促進できることが確認された。また、本発明に係る皮膚外用組成物は、所定期間経過後においても高い改善効果を維持できることが判明した。このことから、トラネキサム酸エステルの皮膚への付与安定性、経皮浸透性、及び皮膚からの長期放出持続性が向上していることが確認された。
Claims (3)
- トラネキサム酸エステル及び/又はその塩(A成分)と、シリコーン油(B成分)と、を含む皮膚外用組成物であって、
前記A成分が、トラネキサム酸セチルエステル塩酸塩であり、
前記B成分が、環状のシリコーン油、及び、鎖状のシリコーン油を含む、
皮膚外用組成物。 - 前記A成分と前記B成分との配合比が質量基準で0.01:100〜100:0.01である、請求項1に記載の皮膚外用組成物。
- 前記皮膚外用組成物は化粧品に用いられるものである、請求項1又は2に記載の皮膚外用組成物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005128631A JP4723899B2 (ja) | 2005-04-26 | 2005-04-26 | 皮膚外用組成物 |
TW095114860A TW200719920A (en) | 2005-04-26 | 2006-04-26 | Topical skin care composition |
PCT/EP2006/004947 WO2006114338A1 (en) | 2005-04-26 | 2006-04-26 | Topical skin care composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005128631A JP4723899B2 (ja) | 2005-04-26 | 2005-04-26 | 皮膚外用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006306744A JP2006306744A (ja) | 2006-11-09 |
JP4723899B2 true JP4723899B2 (ja) | 2011-07-13 |
Family
ID=36685570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005128631A Active JP4723899B2 (ja) | 2005-04-26 | 2005-04-26 | 皮膚外用組成物 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4723899B2 (ja) |
TW (1) | TW200719920A (ja) |
WO (1) | WO2006114338A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008050173A1 (en) * | 2006-10-26 | 2008-05-02 | Chanel Parfums Beaute | Topical skin care composition comprising a tranexamic acid ester |
JP2009143858A (ja) * | 2007-12-14 | 2009-07-02 | Showa Denko Kk | 抗老化化粧料 |
TWI499432B (zh) * | 2009-09-17 | 2015-09-11 | Shiseido Co Ltd | Skin external use |
EP2509559B1 (en) * | 2009-12-11 | 2016-06-22 | Chanel Parfums Beauté | Composition for external use and method for producing the same |
JP5165736B2 (ja) * | 2010-08-06 | 2013-03-21 | 株式会社シャネル化粧品技術開発研究所 | トラネキサム酸エステルの生理学的に許容される塩を含む外用組成物の製造方法 |
JP5570442B2 (ja) | 2011-01-24 | 2014-08-13 | 株式会社シャネル化粧品技術開発研究所 | 水中油型乳化組成物及びその製造方法 |
JP2013237666A (ja) * | 2012-04-16 | 2013-11-28 | Daiichi Sankyo Healthcare Co Ltd | 過労又は慢性疲労に伴う疾患の治療及び/又は予防剤 |
JP2015034155A (ja) * | 2013-08-09 | 2015-02-19 | 丸善製薬株式会社 | 表皮角化細胞増殖促進剤およびatp産生促進剤 |
JP6894223B2 (ja) * | 2016-10-13 | 2021-06-30 | ロート製薬株式会社 | 外用組成物 |
CN109793757B (zh) * | 2019-03-28 | 2021-06-22 | 北京刷新活力健康科技有限公司 | 一种抑制皮肤瘢痕生长的组合物及其制备方法和应用 |
US20220402864A1 (en) * | 2019-11-18 | 2022-12-22 | Actera Ingredients, Inc. | Salts of tranexamic acid esters |
US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0446144A (ja) * | 1990-06-13 | 1992-02-17 | Nippon Saafuakutanto Kogyo Kk | トラネキサム酸エステル及び該エステルを有効成分とする抗色素沈着外用剤 |
JPH04169515A (ja) * | 1990-11-01 | 1992-06-17 | Shiseido Co Ltd | 皮膚外用剤 |
JPH07206636A (ja) * | 1994-01-20 | 1995-08-08 | Shiseido Co Ltd | 化粧料 |
JPH07206632A (ja) * | 1994-01-20 | 1995-08-08 | Shiseido Co Ltd | 皮膚外用剤 |
JPH08291049A (ja) * | 1995-02-25 | 1996-11-05 | Hisamitsu Pharmaceut Co Inc | 非水系油性軟膏基剤及び皮膚外用軟膏剤 |
JP2000500436A (ja) * | 1995-10-20 | 2000-01-18 | ラボラトワール エル.ラフォン | 経皮投与のための組成物 |
JP2002234836A (ja) * | 2001-02-13 | 2002-08-23 | Kinji Ishida | ストレス対応皮膚外用剤 |
JP2003306419A (ja) * | 2002-04-16 | 2003-10-28 | Nikko Chemical Co Ltd | 化粧料 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07215839A (ja) * | 1994-02-04 | 1995-08-15 | Shiseido Co Ltd | 皮膚外用剤 |
JP4074043B2 (ja) * | 2000-03-27 | 2008-04-09 | 株式会社資生堂 | 皮膚基底膜形成促進剤、人工皮膚形成促進剤及び人工皮膚の製造方法 |
-
2005
- 2005-04-26 JP JP2005128631A patent/JP4723899B2/ja active Active
-
2006
- 2006-04-26 WO PCT/EP2006/004947 patent/WO2006114338A1/en active Application Filing
- 2006-04-26 TW TW095114860A patent/TW200719920A/zh unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0446144A (ja) * | 1990-06-13 | 1992-02-17 | Nippon Saafuakutanto Kogyo Kk | トラネキサム酸エステル及び該エステルを有効成分とする抗色素沈着外用剤 |
JPH04169515A (ja) * | 1990-11-01 | 1992-06-17 | Shiseido Co Ltd | 皮膚外用剤 |
JPH07206636A (ja) * | 1994-01-20 | 1995-08-08 | Shiseido Co Ltd | 化粧料 |
JPH07206632A (ja) * | 1994-01-20 | 1995-08-08 | Shiseido Co Ltd | 皮膚外用剤 |
JPH08291049A (ja) * | 1995-02-25 | 1996-11-05 | Hisamitsu Pharmaceut Co Inc | 非水系油性軟膏基剤及び皮膚外用軟膏剤 |
JP2000500436A (ja) * | 1995-10-20 | 2000-01-18 | ラボラトワール エル.ラフォン | 経皮投与のための組成物 |
JP2002234836A (ja) * | 2001-02-13 | 2002-08-23 | Kinji Ishida | ストレス対応皮膚外用剤 |
JP2003306419A (ja) * | 2002-04-16 | 2003-10-28 | Nikko Chemical Co Ltd | 化粧料 |
Also Published As
Publication number | Publication date |
---|---|
WO2006114338A1 (en) | 2006-11-02 |
TW200719920A (en) | 2007-06-01 |
JP2006306744A (ja) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4723899B2 (ja) | 皮膚外用組成物 | |
KR101823036B1 (ko) | 멜라닌 색소 생성 억제제 및 이를 함유하는 화장료 조성물 | |
KR102043485B1 (ko) | 수중유형 유화조성물 | |
KR101496373B1 (ko) | 국소 투여를 위한 아르기닌 헤테로머 | |
US20210346458A1 (en) | Compositions and methods for improving bruising and rejuvenating skin | |
TW200408398A (en) | Chloasma amelioration composition and dullness amelioration composition | |
JP2003128531A (ja) | 皮膚外用剤 | |
KR101986513B1 (ko) | 토코페릴아세테이트를 유효성분으로 함유하는 입술 항노화용 화장료 조성물 | |
JPS61152613A (ja) | 皮膚化粧料 | |
WO2007105706A1 (ja) | 美白用皮膚外用剤及び皮膚の美白方法 | |
JP2016179958A (ja) | 皮膚色素沈着抑制剤 | |
US20200046617A1 (en) | Composition For Combating The Signs Of Ageing Of The Skin And Hair And Nails | |
JP3740069B2 (ja) | 皮膚外用剤 | |
JP5985346B2 (ja) | 皮膚化粧料 | |
JP2012184179A (ja) | 皮膚化粧料 | |
JPH09175983A (ja) | 皮膚外用剤 | |
JP6920031B2 (ja) | 慢性角化型湿疹改善剤 | |
JP2006008550A (ja) | 抗老化剤 | |
JPH09255546A (ja) | 皮膚外用剤 | |
RU2355383C2 (ru) | Косметическое средство на основе коллагеназы микробного происхождения | |
JP2011140442A (ja) | スルフヒドリルオキシダーゼ活性促進剤 | |
JPS62263110A (ja) | 被膚老化予防化粧料 | |
JP2024046365A (ja) | トランスグルタミナーゼ産生促進剤およびその用途 | |
JPS6185308A (ja) | 皮膚化粧料 | |
KR101654225B1 (ko) | 바이칼린-아연착염을 포함하는 여드름 피부 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080421 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20091125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100826 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110202 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110331 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110408 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140415 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4723899 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |